The Valley Desk

NCT02000440 · Interventional trial

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Overall registry status Completed

Phase 2

Conditions Glomerulosclerosis, Focal Segmental

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov